Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
- 120 Downloads
Hepatitis B and hepatitis C are important causes of chronic liver disease globally. Although HBV/HCV coinfection is not uncommon, its epidemiology is poorly defined. Numerous studies provided evidence that coinfection accelerates liver disease progression and increases the risk of hepatocellular carcinoma. By applying new cell culture models to examine the interaction of both viruses, investigators concluded that HBV and HCV replicate in the same hepatocyte without interference. The roles of innate and adaptive immunity in determining the viral replication and disease outcomes still need rigorous investigation. To date, no standard-of-care recommendation exists for HBV/HCV coinfection. Pegylated interferon and ribavirin combination therapy demonstrated similar efficacy in suppressing HCV RNA in coinfection and HCV monoinfection. However, HBV reactivation during therapy can be a challenge. Future clinical trials evaluating the addition of a nucleoside/nucleotide analog for selective patients with HBV/HCV coinfection are essential for successful management of HBV/HCV coinfection.
KeywordsHepatitis B virus Hepatitis C virus Epidemiology Natural history Pathogenesis Pegylated interferon
The author has served on advisory boards for, and received research grants, honoraria, and travel reimbursements from, Bristol-Myers Squibb and Gilead.
Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance
- 9.•• Bellecave P, Gouttenoire J, Gajer M, et al.: Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009, 50:46–55. This study independently concluded that cells with replicating HBV could be infected by HCV without superinfection exclusion.CrossRefPubMedGoogle Scholar
- 28.• Sagnelli E, Coppola N, Pisaturo M, et al.: HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009, 49:1090–1097. This article describes a long-term follow-up Italian study on the outcome of hepatitis C after HBV superinfection. A proportion of patients had prolonged HCV RNA clearance after HBV superinfection.CrossRefPubMedGoogle Scholar
- 37.Tanaka H, Tsukuma H, Yamano H, et al.: Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004, 112:1075–1080.CrossRefPubMedGoogle Scholar
- 54.•• Liu CJ, Chuang WL, Lee CM, et al.: Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496–504 e3. This article describes the largest prospective, randomized, controlled trial using pegylated interferon and ribavirin therapy on HBV and HCV coinfection. This Taiwanese study confirmed high HCV SVR but also high rate of HBV reactivation during combination therapy.CrossRefPubMedGoogle Scholar
- 55.• Potthoff A, Wedemeyer H, Boecher WO, et al.: The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008, 49:688–694. This study reported that HCV genotype 1 and non-1 patients both had excellent SVR in the setting of co-infection. They observed four patients with undetectable serum HBV DNA at baseline had reactivation of HBV after HCV RNA clearance.CrossRefPubMedGoogle Scholar
- 57.• Yu JW, Sun LJ, Zhao YH, et al.: Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009, 29:1485–1493. This study showed that HBV reactivation rate was significantly higher among those who achieved HCV SVR compared to those without SVR.CrossRefPubMedGoogle Scholar